Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 6, 2011, Pages 1200-1206

  Iwaki, T ^a   Tanaka, A ^a   Miyawaki, Y ^b   Suzuki, A ^b   Kobayashi, T ^c   Takamatsu, J ^d   Matsushita, T ^b   Umemura, K ^a   Urano, T ^a   Kojima, T ^b,e   Terao, T ^a   Kanayama, N ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HAMAMATSU MEDICAL CENTER   (Japan)

^d Japan Red Cross Aichi Blood Center   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

Author keywords

Bleeding tendency; Gene deficiencies; Hypermenorrhea; Impaired wound healing; Plasminogen activator inhibitor 1; Serpine1

Indexed keywords

ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; ANTIGEN; BETA1 INTEGRIN; BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 13; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIGEN; SERPINE 1; UNCLASSIFIED DRUG; VITRONECTIN;

ADULT; AFIBRINOGENEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; CASE REPORT; DNA SEQUENCE; EXON; FEMALE; GENE DUPLICATION; HEMOPHILIA; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PHENOTYPE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SERPINE 1 DEFICIENCY; VON WILLEBRAND DISEASE; WILD TYPE; WOUND HEALING IMPAIRMENT;

ANIMALS; CRITICAL ILLNESS; FEMALE; HEMORRHAGE; HOMOZYGOTE; HUMANS; MICE; MICE, KNOCKOUT; MIDDLE AGED; MUTATION; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEQUENCE ANALYSIS, DNA; SERPIN E2; TRANSFECTION; WOUND HEALING;

EID: 79958025276     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04288.x     Document Type: Article

References (41)

1. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
2. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
3. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468-77.
4. Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008; 118: 116-24.
5. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
6. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
7. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35: 356-66.
8. James AH, Manco-Johnson MJ, Yawn BP, Dietrich JE, Nichols WL. von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines. Obstet Gynecol 2009; 114: 674-8.
9. Ichinose A, Asahina T, Kobayashi T. Congenital blood coagulation factor XIII deficiency and perinatal management. Curr Drug Targets 2005; 6: 541-9.
10. Tanaka A, Suzuki Y, Sugihara K, Kanayama N, Urano T. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Life Sci 2009; 85: 220-5.
11. Urano T, Castellino FJ, Ihara H, Suzuki Y, Ohta M, Suzuki K, Mogami H. Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 2003; 1: 2615-20.
12. Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66: 474-8.
13. Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H. Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the gamma-chain that impairs the polymerization of fibrin monomer. J Biochem 1989; 105: 10-4.
14. Matsushita T, Takamatsu J, Kagami K, Takahashi I, Sugiura I, Hamaguchi M, Kamiya T, Saito H. A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report. Am J Hematol 1992; 39: 137-41.
15. Matsushita T, Tanimoto M, Yamamoto K, Sugiura I, Hamaguchi M, Takamatsu J, Kamiya T, Saito H. DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene. J Lab Clin Med 1990; 116: 492-7.
16. Hamaguchi M, Matsushita T, Tanimoto M, Takahashi I, Yamamoto K, Sugiura I, Takamatsu J, Ogata K, Kamiya T, Saito H. Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4). Thromb Haemost 1991; 65: 514-20.
17. Kobayashi T, Terao T, Kojima T, Takamatsu J, Kamiya T, Saito H. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 1990; 29: 235-8.
18. Izumi T, Nagaoka U, Saito T, Takamatsu J, Saito H, Ichinose A. Novel deletion and insertion mutations cause splicing defects, leading to severe reduction in mRNA levels of the A subunit in severe factor XIII deficiency. Thromb Haemost 1998; 79: 479-85.
19. Sugiura I, Matsushita T, Tanimoto M, Takahashi I, Yamazaki T, Yamamoto K, Takamatsu J, Kamiya T, Saito H. Three distinct candidate point mutations of the von Willebrand factor gene in four patients with type IIA von Willebrand disease. Thromb Haemost 1992; 67: 612-7.
20. Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14: 1151-8.
21. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost 2009; 35: 426-38. [doi].
22. Kobayashi T, Asahina T, Maehara K, Itoh M, Kanayama N, Terao T. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest 1996; 42: 66-9.
23. Iwaki T, Sandoval-Cooper MJ, Paiva M, Kobayashi T, Ploplis VA, Castellino FJ. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol 2002; 160: 1021-34.
24. Iwaki T, Castellino FJ. Maternal fibrinogen is necessary for embryonic development. Curr Drug Targets 2005; 6: 535-9.
25. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-8.
26. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004; 95: 637-44.
27. Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation 2010; 122: 1200-9.
28. Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood 2010; 115: 2038-47.
29. Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factorVII. Thromb Haemost 2005; 94: 493-7.
30. Pawlinski R, Fernandes A, Kehrle B, Pedersen B, Parry G, Erlich J, Pyo R, Gutstein D, Zhang J, Castellino F, Melis E, Carmeliet P, Baretton G, Luther T, Taubman M, Rosen E, Mackman N. Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci USA 2002; 99: 15333-8.
31. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
32. Ploplis VA, Carmeliet P, Vazirzadeh S, van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
33. Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008; 14: 1261-8.
34. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93: 2274-81.
35. Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008; 14: 1250-4.
36. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 2001; 86: 640-6.
37. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
38. Chan JC, Duszczyszyn DA, Castellino FJ, Ploplis VA. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001; 159: 1681-8.
39. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180-91.
40. Ploplis VA, Castellino FJ. Attenuation of neointima formation following arterial injury in PAI-1 deficient mice. Ann N Y Acad Sci 2001; 936: 466-8.
41. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-83.